Betadex
CAS 7585-39-9
Betadex (CAS 7585-39-9) is a Phase 3 pharmaceutical compound with 3 bioactivity targets and 18 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | AC50 | 28219.796774193546 nM | 31 | - |
| - | Potency | 23457.683333333334 nM | 6 | - |
| - | IC50 | 19976.309999999998 nM | 1 | - |
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| BETADEX | 1362685 | SU | MTHSPL |
| betadex | 1362685 | SU | MTHSPL |
| Betadex | 1362685 | SU | MTHSPL |
| betadex | 1362685 | IN | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Betadex used for in pharmaceutical contexts?
Betadex (CAS 7585-39-9) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Betadex?
Betadex has 18 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Brain death, Brain herniation, Brain oedema, Drug abuse, Drug screen positive. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Betadex also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Cyclodextrin with EU status "permitted".
What clinical phase is Betadex in?
Betadex is rendered with ChEMBL max phase 3.